MarketCap
Facebook
X
Telegram
Benitec Biopharma Balance Sheet 2025-2011 | BNTC
Brief overview of Benitec Biopharma 's balance sheet structure
The balance sheet is assessed across five available annual reports spanning 2021 to 2025.
Assets rose from $21.4 million to $99.6 million, a gain of +365.8%, while CAGR was about 46.9%. The balance sheet expanded rapidly.
Liability growth of +67.8% trailed asset growth of +365.8%. The funding structure became more resilient.
The equity-to-assets ratio is 97.7%, compared with 93.6% five periods ago. The balance sheet has a substantial internal cushion.
Negative net debt of -$96.9 million means cash holdings are larger than debt obligations.
The cash reserve occupies 98.1% of the balance sheet, previously 92.5%. It is one marker of short-term resilience.
The accumulated result is -$228.2 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.
Conclusion
Benitec Biopharma 's balance sheet looks resilient: assets are supported by substantial equity, while debt does not overwhelm financial flexibility.
Annual Balance Sheet Benitec Biopharma
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-96.9 M | - | -1.92 M | -3.25 M | - | -9.4 M | -15.7 M | -11.8 M | -13.4 M | -13.6 M | -16.7 M | -20.5 M | -28.6 M | - | - |
Long Term Debt |
495 K | - | 284 K | 559 K | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
354 K | 284 K | 275 K | 252 K | 213 K | 192 K | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 213 K | - | 35.3 K | 26.9 K | 13.4 K | - | - | - | - | - |
Total Current Liabilities |
1.8 M | 4.92 M | 3.98 M | 2.53 M | 1.37 M | 1.14 M | - | - | - | - | - | - | - | - | - |
Total Liabilities |
2.3 M | 4.96 M | 4.26 M | 3.09 M | 1.37 M | 1.35 M | 2.64 M | 1.91 M | 891 K | 786 K | 1.26 M | 1.55 M | 872 K | - | - |
Retained Earnings |
-228 M | -190 M | -181 M | -148 M | -130 M | -117 M | -98.9 M | -108 M | -104 M | -98.1 M | -82.7 M | -101 M | -87.9 M | - | - |
Total Assets |
99.6 M | 52.2 M | 4.46 M | 5.97 M | 21.4 M | 11.6 M | 19.2 M | 15.7 M | 17.4 M | 14.9 M | 19.6 M | 24 M | 31.5 M | - | - |
Cash and Cash Equivalents |
97.7 M | 50.9 M | 2.48 M | 4.06 M | 19.8 M | 9.8 M | 15.7 M | - | - | - | - | - | - | - | - |
Book Value |
97.3 M | 47.2 M | 202 K | 2.88 M | 20 M | 10.2 M | 16.6 M | 13.8 M | 16.5 M | 14.1 M | 18.3 M | 22.5 M | 30.6 M | - | - |
Total Shareholders Equity |
97.3 M | 47.2 M | 202 K | 2.88 M | 20 M | 10.2 M | 16.6 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Benitec Biopharma
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
394 K | 519 K | 403 K | 519 K | 403 K | 495 K | 613 K | - | - | - | 62 K | 137 K | 211 K | 284 K | 354 K | 422 K | 491 K | 559 K | 635 K | 698 K | 760 K | - | - | 108 K | 161 K | 213 K | 213 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
3.67 M | 3.32 M | 2.43 M | 3.32 M | 2.43 M | 2.3 M | 7.64 M | 3.13 M | 4.59 M | 4.96 M | 3.5 M | 5.88 M | 4.74 M | 4.26 M | 3.51 M | 2.91 M | 3.5 M | 3.09 M | 2.54 M | 3.18 M | 2.36 M | 1.37 M | 1.37 M | 887 K | 1.18 M | 1.35 M | 1.35 M | - | - | 2.64 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-261 M | -249 M | -237 M | -249 M | -237 M | -228 M | -212 M | -203 M | -195 M | -190 M | -185 M | -181 M | -174 M | -168 M | -163 M | -159 M | -153 M | -148 M | -143 M | -140 M | -135 M | -130 M | -130 M | -122 M | -119 M | -117 M | -117 M | - | - | -109 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
187 M | 191 M | 96 M | 191 M | 96 M | 99.6 M | 105 M | 79.1 M | 68.8 M | 52.2 M | 15 M | 21.4 M | 27.1 M | 4.46 M | 8.22 M | 11.9 M | 18.1 M | 5.97 M | 10.1 M | 14 M | 17.8 M | 21.4 M | 21.4 M | 15.5 M | 8.92 M | 11.6 M | 11.6 M | - | - | 19.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
185 M | 189 M | 94.5 M | 189 M | 94.5 M | 97.7 M | 104 M | 78.3 M | 67.9 M | 50.9 M | 14.2 M | 20.4 M | 25.9 M | 2.49 M | 6.56 M | 10.6 M | 16.5 M | 4.06 M | 8.63 M | 12.3 M | 15.7 M | 19.8 M | 19.8 M | 14 M | 7.45 M | 14 M | 7.45 M | 13.8 M | 16.6 M | 15.7 M | - | - | - | 11.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
183 M | 187 M | 93.6 M | 187 M | 93.6 M | 97.3 M | 97.6 M | 75.9 M | 64.2 M | 47.2 M | 11.5 M | 15.5 M | 22.3 M | 202 K | 4.71 M | 8.99 M | 14.6 M | 2.88 M | 7.52 M | 10.8 M | 15.5 M | 20 M | 20 M | 14.6 M | 7.74 M | 10.2 M | 10.2 M | - | - | 16.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
183 M | 187 M | 93.6 M | 187 M | 93.6 M | 97.3 M | 97.6 M | 75.9 M | 64.2 M | 47.2 M | 11.5 M | 15.5 M | 22.3 M | 202 K | 4.71 M | 8.99 M | 14.6 M | 2.88 M | 7.52 M | 10.8 M | 15.5 M | 20 M | 15.5 M | 14.6 M | 14.6 M | 14.6 M | 7.74 M | 15.3 M | 17 M | 16.6 M | - | - | - | 13.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Benitec Biopharma , providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Canada
China
Britain
France
Israel
Germany
Russia
Belgium
Cayman-islands
